Luxury giant Kering Ventures, overseeing brands like Gucci and Saint Laurent, recently backed Italian biotech company SQIM with an €11 million investment. This capital injection, also supported by CDP Venture Capital and the European Circular Bioeconomy Fund, marks a strategic pivot towards mycelium-based leather alternatives within luxury fashion, according to vegconomist. It positions advanced material science to integrate into high-end product lines by 2026.
Luxury brands pour millions into bio-fabricated materials, drawn by their sustainability promise. Yet, the industry grapples with the complex challenge of commercializing these innovations at scale. Moving them from laboratory breakthroughs to widespread production remains a hurdle. This tension between ambitious investment and persistent scaling defines the current landscape.
Bio-fabricated materials will become a significant part of luxury fashion's future. Their true market penetration, however, hinges on overcoming production scalability and cost-efficiency hurdles. This strategic bet aims to redefine luxury, making bio-fabrication the new standard, not merely a substitute.
The Rise of Mycelium: A New Era for Luxury Materials
Italian biotech company SQIM has already introduced Ephea Uma, a mycelium-based material featured in a global luxury accessories collection. This launch advances bio-fabricated leather alternatives for luxury fashion. SQIM operates two distinct material brands: Ephea, for fashion and accessories, and Mogu, for interior design and architecture. This diversification showcases mycelium technology's versatility. Microorganisms like fungi can produce materials mimicking leather textures, utilizing plant-based protein or agricultural by-products, as highlighted by Earth. These advancements move away from traditional animal-derived or synthetic materials towards biologically engineered alternatives. SQIM's expansion into both luxury fashion and interior design confirms mycelium is not a niche solution. It is a versatile platform poised to disrupt multiple industries, creating a new class of bio-manufacturers that will challenge established material supply chains.
